BridgeBio Pharma (BBIO) Asset Writedowns and Impairment (2021 - 2022)
BridgeBio Pharma's (BBIO) quarterly Asset Writedowns and Impairment came in at $67000.0 in Q3 2022, down 99.47% quarter-over-quarter from $12.7 million in Q1 2022.
BridgeBio Pharma (BBIO) Asset Writedowns and Impairment (2021 - 2022) Analysis & Trends
BridgeBio Pharma has disclosed Asset Writedowns and Impairment across 2 years of filings, most recently posting $67000.0 for Q3 2022.
- Asset Writedowns and Impairment for Q3 2022 came in at $67000.0, changed N/A year-over-year; the trailing twelve-month figure through Jun 2023 was $67000.0 (down 99.28% YoY), and the FY2024 annual result was $271000.0, changed N/A from the prior year.
- Asset Writedowns and Impairment came in at $67000.0 for Q3 2022 at BridgeBio Pharma, down from $12.7 million in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $12.7 million in Q1 2022 to a low of -$3.3 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | BridgeBio Pharma | 12.90 Bn | 11.97 Bn | 184.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 67,000.00 |
| Sep 30, 2022 | 67,000.00 |
| Mar 31, 2022 | 12.65 Mn |
| Mar 31, 2022 | 12.65 Mn |
| Dec 31, 2021 | -3.30 Mn |
| Dec 31, 2021 | -3.30 Mn |
| Mar 31, 2021 | 3.30 Mn |
| Mar 31, 2021 | 3.30 Mn |